Commenting on the development, Pfizer Chairman and CEO Ian Read said: "We continue to believe that our final proposal was compelling and represented full value for AstraZeneca based on the information that was available to us."
US drug major Pfizer today shelved its USD 117-billion takeover bid of AstraZenaca on the day of expiry of the offer as the British pharmaceutical company remained firm in opposing the deal.
"Following the AstraZeneca board's rejection of the proposal, Pfizer announces that it does not intend to make an offer for AstraZeneca," the company said in a statement.
Commenting on the development, Pfizer Chairman and CEO Ian Read said: "We continue to believe that our final proposal was compelling and represented full value for AstraZeneca based on the information that was available to us."
He further said the pursuit of this transaction was a potential enhancement to the company's existing strategy.
On May 18, 2014, Pfizer had announced that it had made a final proposal to AstraZeneca to make an offer to combine the two companies.
The US firm had urged "supportive AstraZeneca shareholders to urge the AstraZeneca board to begin substantive engagement with Pfizer and extend the period for such talks prior to the May 26 deadline for making an offer".
Pfizer Inc, the New York-based maker of lockbuster drugs such as Lipitor and Viagra, had made a final offer of 55 pounds a share to Astrazeneca on May 18, which was 15 per cent higher than its last bid made on May 2.
Reacting to the final proposal, AstraZeneca had said it undervalued the company and "its attractive prospects and has been rejected by the board of AstraZeneca".
Pfizer had earlier approached AstraZeneca on January 5 and April 26 with a proposal to acquire the company for USD 100 billion. On May 2, the company had raised the offer to USD 106 billion.
Under the final proposal, Pfizer and AstraZeneca shareholders would have owned approximately 74 per cent and 26 per cent, respectively, of the combined company.
AstraZeneca's products include drugs to treat cancer, gastrointestinal and cardiovascular and metabolic diseases.
AstraZeneca stock price
On February 17, 2014, AstraZeneca Pharma closed at Rs 836.75, up Rs 22.75, or 2.79 percent. The 52-week high of the share was Rs 1240.00 and the 52-week low was Rs 595.00.
The latest book value of the company is Rs 39.90 per share. At current value, the price-to-book value of the company was 20.97.
Anda sedang membaca artikel tentang
Pfizer gives up USD 117bn pursuit of AstraZenaca
Dengan url
http://gayafashionshow.blogspot.com/2014/05/pfizer-gives-up-usd-117bn-pursuit-of.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Pfizer gives up USD 117bn pursuit of AstraZenaca
namun jangan lupa untuk meletakkan link
Pfizer gives up USD 117bn pursuit of AstraZenaca
sebagai sumbernya
0 komentar:
Posting Komentar